Duell J, Lammers PE, Djuretic I, et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther. 2019;106(4):781–91. https://doi.org/10.1002/cpt.1396.

Article  PubMed  PubMed Central  Google Scholar 

Middleton MR, McAlpine C, Woodcock VK, et al. A TCR/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma. Clin Cancer Res. 2020;26(22):5869–78. https://doi.org/10.1158/1078-0432.CCR-20-1247.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liddy N, Bossi G, Adams KJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012;18(6):980–7. https://doi.org/10.1038/nm.2764.

Article  CAS  PubMed  Google Scholar 

Albayrak G, Wan PKT, Fisher K, Seymour LW. T cell engagers: expanding horizons in oncology and beyond. Br J Cancer. 2025;133(9):1241–9. https://doi.org/10.1038/s41416-025-03125-y.

Article  PubMed  PubMed Central  Google Scholar 

Le X, Zhang Y, Ma J. Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database. Expert Opin Drug Saf. 2025;24(7):821–30. https://doi.org/10.1080/14740338.2025.2470875.

Article  CAS  PubMed  Google Scholar 

Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol. 2004;122(3):565–73. https://doi.org/10.1046/j.0022-202X.2004.12628.x.

Article  CAS  PubMed  Google Scholar 

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179(3):1005–9. https://doi.org/10.1084/jem.179.3.1005.

van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142–58. https://doi.org/10.1016/S0140-6736(23)00521-4.

Article  PubMed  Google Scholar 

US FDA. FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma. January 26, 2022. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma. [Accessed 16 Jun 2025].

European Medicines Agency. Kimmtrak. April 22, 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kimmtrak. [Accessed 10 Jul 2025].

Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256–66. https://doi.org/10.1056/NEJMoa2304753.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carvajal RD, Butler MO, Shoushtari AN, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med. 2022;28(11):2364–73. https://doi.org/10.1038/s41591-022-02015-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riew GJ, Hijaz BA, Haq R, Chen ST, LeBoeuf NR, Shi CR. Severity and progression of dermatologic adverse events associated with tebentafusp: a retrospective multicenter cohort study. J Am Acad Dermatol. 2025. https://doi.org/10.1016/j.jaad.2025.06.020.

Article  PubMed  Google Scholar 

Carvajal RD, Nathan P, Sacco JJ, et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol. 2022;40(17):1939–48. https://doi.org/10.1200/JCO.21.01805.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hassel JC, Berking C, Forschner A, et al. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp. Eur J Cancer. 2023;191:112986. https://doi.org/10.1016/j.ejca.2023.112986.

Article  CAS  PubMed  Google Scholar 

Pham JP, Star P, Ardolino L, Smith A, Joshua AM. A review of the cutaneous toxicities of tebentafusp: featuring two cases involving superficial bullous reactions. Australas J Dermatol. 2022;63(3):e279–82. https://doi.org/10.1111/ajd.13866.

Article  PubMed  Google Scholar 

Rodriguez I, Norman T, Guenther J, et al. Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights. Clin Exp Dermatol. 2024;49(4):392–4. https://doi.org/10.1093/ced/llad387.

Article  PubMed  Google Scholar 

Hassel JC, Stanhope S, Greenshields-Watson A, et al. Tebentafusp induces a T-cell-driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J Invest Dermatol. 2025;145(3):559-72.e9. https://doi.org/10.1016/j.jid.2024.03.048.

Article  CAS  PubMed  Google Scholar 

Tomsitz D, Kerl K, French LE, Heinzerling L. Clinical and pathological characterization of tebentafusp-associated skin toxicity: a cohort study with 33 patients. J Am Acad Dermatol. 2024;91(6):1136–42. https://doi.org/10.1016/j.jaad.2024.08.037.

Article  CAS  PubMed  Google Scholar 

Fahmy LM, Schreidah CM, McDonnell DE, Carvajal RD, Magro CM, Geskin LJ. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatol Online J. 2023. https://doi.org/10.5070/D329662993.

Article  PubMed  Google Scholar 

Rudin CM, Reck M, Johnson ML, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66. https://doi.org/10.1186/s13045-023-01464-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

US Food and Drug Administration. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. May 16, 2024. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer. [Accessed 14 Jul 2025].

European Medicines Agency. EU/3/23/2876: orphan designation for treatment of small cell lung cancer. April 11, 2024. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2876. [Accessed 14 Jul 2025].

Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;41(16):2893–903. https://doi.org/10.1200/JCO.22.02823.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiang AC, Olmedo Garcia ME, Carlisle JW, et al. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open. 2025;10(4):104538. https://doi.org/10.1016/j.esmoop.2025.104538.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hummel HD, Ahn MJ, Blackhall F, et al. Patient-reported outcomes for patients with previously treated small cell lung cancer receiving tarlatamab: results from the DeLLphi-301 phase 2 trial. Adv Ther. 2025;42(4):1950–64. https://doi.org/10.1007/s12325-025-03136-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063–75. https://doi.org/10.1056/NEJMoa2307980.

Article  CAS  PubMed  Google Scholar 

Przepiorka D, Ko CW, Deisseroth A, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035–9. https://doi.org/10.1158/1078-0432.CCR-15-0612.

Article  CAS  PubMed  Google Scholar 

Ransohoff JD, Kwong BY. Cutaneous adverse events of targeted therapies for hematolymphoid malignancies. Clin Lymphoma Myeloma Leuk. 2017;17(12):834–51. https://doi.org/10.1016/j.clml.2017.07.005.

Article  PubMed  Google Scholar 

US Food and Drug Administration. FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. 2024. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell. [Accessed 18 Aug 2025].

Parisi R, Cowen EA, Gu S, et al. Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab. Leuk Lymphoma. 2023;64(9):1583–7. https://doi.org/10.1080/10428194.2023.2221756.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liau MM, Long V, Huang J, Jaffar H. Blinatumomab-associated vasculitis. JAAD Case Rep. 2017;3(5):395–7.